In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...
Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...
Zacks Investment Research on MSN22h
FDA Expands Exelixis Cabometyx Label for Neuroendocrine TumorsExelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...
Zacks Investment Research on MSN1d
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also ...
ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...
Alan Tan, MD, discusses the 8-year follow-up data from the CheckMate 214 trial of patients with advanced renal cell carcinoma.
Reports revenue RMB 980.7M vs. RMB 221.9M last year. Dajun Yang, CEO, said, “As we reflect on our achievements in 2024, I am delighted to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback